3
Aspergillus fumigatus is generally susceptible to the triazole antifungals, such as itraconazole, 34 voriconazole and posaconazole, however over the last decade azole-resistance was emerged 35 globally (1). Resistant isolates have been found both in patients undergoing azole treatment and 36 naïve patients, as well as in the environment. In the prospective study SCARE (Surveillance
37
Collaboration on Aspergillus Resistance in Europe) the rate of azole resistance among A. fumigatus 38 clinical isolates was 3.2% (range 0-26.1%) (2).
39
Several resistance mechanisms have been identified, most caused by point mutations on the cyp51A 40 gene that encodes the azole target enzyme, the lanosterol 14-α-demetylase, required for the 41 biosynthesis of ergosterol. Some mutations are responsible for multi-azole resistance and this 42 resistance has a great impact on the outcome in patients with both invasive aspergillosis and chronic 43 disease because it reduces few drug therapeutic options available (3). The most frequently reported 44 mutation is on the 98 codon, consisting of a substitution of a histidine with a leucine always 45 associated with a 34-bp tandem repeat in the promoter region (TR34/L98H) resulting in an 46 overexpression of the cyp51A (4). This molecular mechanism was initially found in clinical and 47 environmental isolates from The Netherlands (5). Some studies are suggesting that the large use of 48 triazole fungicides in agriculture may have selected the strains carrying this mutation (6, 7).
49
The aims of the present study were to investigate the prevalence of azole resistance among A.
50
fumigatus clinical isolates from a large Italian historical culture collection and to identify the year 51 the TR34/L98H mutation appeared in Italy. 
61
The method was preliminarely validated using five azole susceptible and five azole resistant A.
62
fumigatus isolates with different mechanisms of resistance. An A. fumigatus resistant strain (IUM 63 11-0396; MIC >16, 2 and 2 mg/L for itraconazole, voriconazole and posaconazole, respectively) 64 was used to validate each test. Plates, incubated at 37°C, were examined after 48 hours (Figure 1 ).
65
Isolates grown on azoles-containing agar plates were tested by broth microdilution method 
75
A.fumigatus sensu strictu isolates were identified by amplification and sequencing of a portion of 76 the β-tubulin gene, as described previously (4).
77
In addition, the entire cyp51A gene and its promoter, were sequenced as previously described (11) 78 to detect the presence of the point mutations. The cyp51A sequence from A. fumigatus strain 237
79
(GenBank accession number: AF338659) was used as wild type reference.
80
Azole-resistant isolates were genotyped by microsatellite analysis using the primers STRAf3A, 
84
A total of 78 isolates showed positive or weak growth on at least one azole containing plate; 31 85 isolates were confirmed resistant according to broth microdilution method.
86 Table 1 shows the number of itraconazole resistant isolates according to the year of isolation. No 87 resistance was detected in isolates collected from 1995 to 1997 (85 isolates from 62 patients).
88
Starting from 1998 the resistance rate was 6.9%, namely 31 resistant out of 448 screened isolates. A 89 total of 24 patients (6.25%) harboured a resistant isolate. This resistance rate is consistent with the 90 data from other European countries (13).
91
The emergence of the azole-resistant strains from 1998 is also supported by the network analysis of 
96
The characteristics of the resistant isolates, the MIC values and the type of mutation are reported in 97 
